Liza Laws

Brighton, United Kingdom

Trained journalist, currently senior editor for 2 pharma sites, Arsenal observer, Smiths fan, wannabe novelist...and genuine salad fan ♥️

Featured in: Favicon

outsourcing-pharma.com Favicon

biopharma-reporter.com

linkedin.com Favicon

nutraingredients.com Favicon

labiotech.eu Favicon

newsbreak.com Favicon

foodnavigator-usa.com Favicon

dairyreporter.com Favicon

confectionerynews.com Favicon

bakeryandsnacks.com + 4 more

Articles

Cherwell introduces Redipor TwistLock plate range to aid microbial environmental monitoring

1 week ago | discover-pharma.com | Liza Laws

Tags: Azzur Group, Biologics, Biopharma, biopharmaceuticals, Biotechnology, CDMO, Cell Therapy, Chrysalis, cleanrooms, flexible manufacturing, Gene Therapy, GMP, industry expansion, innovation, operational excellenceCleanroom microbiology expert Cherwell, an Analytichem company, has launched a new range of plated prepared media designed to help protect samples, improve data integrity and aid automated workflows in microbial environmental monitoring (EM).
Cherwell introduces Redipor TwistLock plate range to aid microbial environmental monitoring

1 week ago | discover-pharma.com | Liza Laws

Tags: AnalytiChem, automated workflows, Biotechnology, Cherwell, cleanrooms, contamination control, Data Integrity, GMP, ICH Q9, microbial environmental monitoring, pharmaceuticals, plate media, Redipor TwistLockCleanroom microbiology expert Cherwell, an Analytichem company, has launched a new range of plated prepared media designed to help protect samples, improve data integrity and aid automated workflows in microbial environmental monitoring (EM).
Chrysalis launches following cleanroom asset acquisition and strategic investment

1 week ago | discover-pharma.com | Liza Laws

Tags: Azzur Group, Biologics, Biopharma, biopharmaceuticals, Biotechnology, CDMO, Cell Therapy, Chrysalis, cleanrooms, flexible manufacturing, Gene Therapy, GMP, industry expansion, innovation, operational excellenceChrysalis, a GMP-compliant space and service provider, has formally launched following its acquisition of cleanroom facility assets from Azzur Group alongside securing a strategic ownership investment to aid its expansion.
Ethris signs strategic collaboration with Thermo Fisher Scientific to provide access to mRNA technology platforms

1 week ago | discover-pharma.com | Liza Laws

Tags: Biologics, biopharmaceuticals, Biotechnology, biotechnology partnerships, CDMO, clinical trial, collaboration, Drug Development, Ethris, GMP, innovation, manufacturing, mRNA, nasal delivery, respiratory disease, Thermo Fisher Scientific, vaccines Partnership further validates Ethris’ novel technology platform based on stabilized non-immunogenic mRNA, which overcomes the innate instability and immunity of mRNA Ethris GmbH, a clinical-stage biotechnology company pioneering next-generation...
Symbiosis expands global reach with key appointment of Angelika Rublack as senior business development manager

1 week ago | discover-pharma.com | Liza Laws

Tags: Biopharma, biopharmaceuticals, Biotechnology, business development, CDMO, CMO services, collaborative relationships, fill-finish, GMP, industry appointments, international expansion, pharmaceuticals, Sterile Manufacturing, supplier partnerships, Symbiosis Symbiosis Pharmaceutical Services (Symbiosis), a global contract manufacturing organization (CMO) specializing in sterile manufacture of injectable drug products, has appointed Angelika Rublack as senior business development manager to...
IFFIm’s Sterling transaction pushes vaccine finance past $10 billion milestone

2 weeks ago | discover-pharma.com | Liza Laws

Tags: children’s health, Featured, financial innovation, Gavi, Global Health, health equity, HPV vaccines, IFFIm, international finance, investor confidence, low-income countries, malaria vaccines, sustainable development, sustainable investment, UK aid, UK financial markets, vaccine financing, vaccines The International Finance Facility for Immunisation (IFFIm) today announced the settlement of its £300 million, 3-year, 4.25% fixed-rate note — the third Sterling-denominated transaction it...
Enhanced Genomics appoints biotech veteran Dietrich Stephan as chair to drive next-gen target discovery

2 weeks ago | discover-pharma.com | Liza Laws

Tags: 3D multi-omics, autoimmune disease, BGF, biotech leadership, common diseases, Dietrich Stephan, drug discovery, Enhanced Genomics, genomics, NIH, patient stratification, Precision Medicine, target identificationEnhanced Genomics has appointed leading biotechnology entrepreneur Dietrich Stephan as chair of its board of directors, strengthening the company’s leadership as it accelerates drug target discovery for common diseases using its proprietary 3D multi-omics platform.
MaxCyte and Ori Biotech integrate platforms to improve cell therapy manufacturing

2 weeks ago | discover-pharma.com | Liza Laws

Tags: autologous therapies, Cell Therapy, CGT scalability, closed system manufacturing, CRISPR, electroporation, Gene Editing, manufacturing, MaxCyte, Ori Biotech, T cellsCD19 CAR CRISPR T cell workflow used to demonstrate shortened timelines and improved yieldMaxCyte and Ori Biotech have entered into a strategic collaboration to improve the efficiency, scalability and reproducibility of autologous cell therapy manufacturing, the companies announced today.
Sofinnova Partners and NVIDIA join forces to boost European AI in life sciences

2 weeks ago | discover-pharma.com | Liza Laws

Tags: AI, BioCorteX, Bioptimus, computational biology, Cure51, DGX Cloud Lepton, digital medicine, drug discovery, European biotech, genomics, GPU, Latent Labs, NVIDIA, Precision Medicine, Sofinnova PartnersSofinnova Partners has announced a new collaboration with NVIDIA to accelerate the AI capabilities of its life sciences portfolio companies, offering a powerful edge in a market estimated to exceed $100 billion.
Chiesi and Key2Brain extend global partnership to advance blood-brain barrier-crossing therapies for ultra-rare diseases

2 weeks ago | discover-pharma.com | Liza Laws

Tags: alpha-mannosidosis, BBB-crossing platform, biotech collaboration, Blood Brain Barrier, Chiesi, Elisabet Sjöström, enzyme replacement therapy, Giacomo Chiesi, global licensing deal, Key2Brain, Krabbe disease, lysosomal storage disorders, Neurodegeneration, rare diseases Chiesi Group has signed a worldwide license agreement with Swedish biotech Key2Brain to accelerate the development of blood-brain barrier (BBB)-crossing enzyme replacement therapies (ERTs) for lysosomal storage disorders,...

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →

X (formerly Twitter)

Followers: 399
Tweets: 973
DMs Open: No

Liza Laws @Liza77Laws

26 Aug 24

https://t.co/LVBTxc1wqJ

Liza Laws @Liza77Laws

24 Aug 24

RT @H1co_: H1 and @GRM_Global are on a mission to provide critical #medicalaid in Ukraine. Our CEO talks with @Liza77Laws at @OutsourcPharm…

Liza Laws @Liza77Laws

21 Aug 24

RT @TheFigen_: The fine line between male and female intelligence. 😂 https://t.co/p4RlfazsVI

Liza Laws

Articles

Cherwell introduces Redipor TwistLock plate range to aid microbial environmental monitoring

Cherwell introduces Redipor TwistLock plate range to aid microbial environmental monitoring

Chrysalis launches following cleanroom asset acquisition and strategic investment

Ethris signs strategic collaboration with Thermo Fisher Scientific to provide access to mRNA technology platforms

Symbiosis expands global reach with key appointment of Angelika Rublack as senior business development manager

IFFIm’s Sterling transaction pushes vaccine finance past $10 billion milestone

Enhanced Genomics appoints biotech veteran Dietrich Stephan as chair to drive next-gen target discovery

MaxCyte and Ori Biotech integrate platforms to improve cell therapy manufacturing

Sofinnova Partners and NVIDIA join forces to boost European AI in life sciences

Chiesi and Key2Brain extend global partnership to advance blood-brain barrier-crossing therapies for ultra-rare diseases

Contact details

Emails

Socials & Sites

X (formerly Twitter)